Hepatitis B Virus Perinatal Exposure Follow-up Panel, Serum
Use
This test is intended to determine hepatitis B virus infection and immunity status in infants born to mothers with chronic hepatitis B, whether or not they have received perinatal prophylaxis. It aids in identifying acute or chronic hepatitis B infection and assesses immunity status post-recovery or post-vaccination.
Special Instructions
Not provided.
Limitations
Assay performance has not been established for grossly icteric, lipemic, or hemolyzed specimens, or specimens containing particulate matter. It also does not differentiate between a vaccine-induced immune response and recovery from HBV infection. Testing may not be suitable for cadaveric or heat-inactivated specimens.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 77190-7 - HBV core + surf Ab + surf Ag Pnl Ser
- 13952-7 - HBV core Ab SerPl Ql IA
- 10900-9 - HBV surface Ab Ser Ql IA
- 5193-8 - HBV surface Ab SerPl IA-aCnc
- 5196-1 - HBV surface Ag SerPl Ql IA
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.2 mL
Minimum Volume
0.9 mL
Container
Plastic vial
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions and aliquot serum into a plastic vial.
Patient Preparation
For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements containing biotin.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 6 days |
| Frozen | 90 days |